Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios davur s.l. - selegilina hidrocloruro - comprimido - 5 mg - selegilina hidrocloruro 5 mg - selegilina

USA - engelsk - NLM (National Library of Medicine)

apotex corp. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 5 mg - selegiline capsules, usp are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of 'off' time, and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).  selegiline is contraindicated in patients with a known hypersensitivity to this drug. selegiline is contraindicated for use with meperidine (demerol & other trade names). this contraindication is often extended to other opioids. (see drug interactions .)

USA - engelsk - NLM (National Library of Medicine)

golden state medical supply, inc. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 5 mg - selegiline hydrochloride capsules, usp are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walki

USA - engelsk - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 5 mg - selegiline hydrochloride tablets are indicated as an adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that selegiline hydrochloride tablets have any beneficial effect in the absence of concurrent levodopa therapy. evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline hydrochloride tablets or placebo in patients receiving levodopa/carbidopa. selegiline hydrochloride tablets were significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressin

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - selegilina - comprimido - 5 mg - selegilina, cloridrato 5 mg - selegiline - genérico - duração do tratamento: longa duração

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

mylan ab - selegilinhydroklorid - tablett - 10 mg - selegilinhydroklorid 10 mg aktiv substans; laktosmonohydrat hjälpämne - selegilin

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

mylan ab - selegilinhydroklorid - tablett - 5 mg - laktosmonohydrat hjälpämne; selegilinhydroklorid 5 mg aktiv substans - selegilin

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. - selegilinehydrochloride; - tablet - selegiline

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

neuraxpharm arzneimittel gmbh (1009339) - selegilinhydrochlorid - tablette - selegilinhydrochlorid (21954) 5 milligramm

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

f5 profas, s.l. - selegilina hidrocloruro - excipientes: manitol (e-421) - agentes dopaminÉrgicos - inhibidores de la monoaminoxidasa b - selegilina